1887
Volume 2021, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Objective: Clinical methods that are generally used to evaluate the completeness of medical abortion are not reliable. Ultrasound imaging and beta-human chorionic gonadotropin (β-hCG) measurements are used to diagnose completed medical abortion, but a precise evaluation of these two methods has shown contradictory results. The purpose of this study is to evaluate the agreement of serum β-hCG measurement and ultrasound imaging to confirm complete medical abortion.

Materials and Methods: This study was conducted on pregnant women who had been referred to our center for medical abortion from 2015 to 2017. All cases occurred in the first trimester of pregnancy. They obtained one or two doses of vaginal misoprostol for medical abortion. Success rate of medical abortion was measured by both transvaginal ultrasound imaging and consecutive serum β-hCG measurements two to four weeks after initial treatment.

Results: Among the 275 women who completed the study, complete medical abortion was confirmed by serum β-hCG in 231 women (84.3%) and transvaginal ultrasound imaging in 195 women (70.8%) after two weeks. All remaining cases completed the medical abortion after an additional two weeks, confirmed by both transvaginal ultrasound imaging and serum β-hCG. The sensitivity, specificity, positive, and negative predictive values of β-hCG were 95.2%, 86.7%, 84%, and 70%, respectively; and these values for transvaginal ultrasound imaging were 68.5% 64.5%,77%, and 30.%, respectively, for the diagnosis of completed medical abortion.

Conclusion: Serum β-hCG measurement is as effective as transvaginal ultrasound imaging to confirm successful medical abortion in early pregnancy.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2021.22
2021-07-12
2024-11-06
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2021/2/qmj.2021.22.html?itemId=/content/journals/10.5339/qmj.2021.22&mimeType=html&fmt=ahah

References

  1. Nassef AH, Mohammed NH, Ibrahim SM. Ultrasonograph versus β-human chorionic gonadotropin titer for verification of termination of missed first trimester miscarriage. Sci J Al-Azhar Med Fac Girls. 2018; 2:(3):264.
    [Google Scholar]
  2. Behnamfar F, Mahdian M, Rahimi F, Samimi M. Misoprostol abortion: ultrasonography versus beta-hCG testing for verification of effectiveness. Pak J Med Sci. 2013; 29:(6):1367–70. doi:10.12669/pjms.296.3361.
    [Google Scholar]
  3. Moseson H, Herold S, Filippa S, Barr-Walker J, Baum S, Gerdts C. Self-managed abortion: a systematic scoping review. Best Pract Res Clin Obstet Gynaecol. 2020;63:87–110. doi:10.1016/j.bpobgyn.2019.08.002.
    [Google Scholar]
  4. Mahmoudiani S, Ahmadi AY, Javadi AF. The prevalence and influential factors of abortion in the women in the rural areas of Fars Province, Iran (2015). Iran J Nurs. 2018; 31:(115):51–61.
    [Google Scholar]
  5. Guillaume A, Rossier C, Reeve P. Abortion around the world. An overview of legislation, measures, trends, and consequences. Population. 2018; 73:(2):217–306.
    [Google Scholar]
  6. Barnhart K, Sammel M, Chung K, Zhou L, Hummel A, Guo W. Decline of serum human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve. Obstet Gynecol. 2004; 104:(5):975–81. doi:10.1097/01.AOG.0000142712.80407.fd.
    [Google Scholar]
  7. Susheela S, Wulf D, Hussain R, Bankole A, Sedgh G. Abortion worldwide: a decade of uneven progress. Guttmacher Institute; 2009.
    [Google Scholar]
  8. Rasch V, Kipingili R. Unsafe abortion in urban and rural Tanzania: method, provider and consequences. TM & IH. 2009; 14:(9):1128–33. doi:10.1111/j.1365-3156.2009.02327.x.
    [Google Scholar]
  9. Raymond EG, Harrison MS, Weaver MA. Efficacy of misoprostol alone for first-trimester medical abortion: a systematic review. Obstet Gynecol. 2019; 133:(1):137–47. doi:10.1097/aog.0000000000003017.
    [Google Scholar]
  10. Sousa A, Lozano R, Gakidou E. Exploring the determinants of unsafe abortion: improving the evidence base in Mexico. Health Policy Plan. 2010; 25:(4):300–10. doi:10.1093/heapol/czp061.
    [Google Scholar]
  11. Cubo Nava A, Soto Pino ZM, Haro Pérez AM, Hernández Hernández ME, Doyague Sánchez MJ, Sayagués Manzano JM. Medical versus surgical treatment of first trimester spontaneous abortion: a cost-minimization analysis. PLOS ONE. 2019; 14:(1):e0210449.
    [Google Scholar]
  12. Wu HL, Marwah S, Wang P, Wang QM, Chen XW. Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis. Sci Rep. 2017; 7:(1):1664.doi:10.1038/s41598-017-01892-0.
    [Google Scholar]
  13. Fielding SL, Schaff EA, Nam NY. Clinicians' perception of sonogram indication for mifepristone abortion up to 63 days. Contraception. 2002; 66:(1):27–31. doi:10.1016/s0010–7824(02)00316-5.
    [Google Scholar]
  14. Le Lous M, Gallinand AC, Laviolle B, Peltier L, Nyangoh Timoh K, Lavoué V. Serum hCG threshold to assess medical abortion success. Eur J Contracep Reprod Health Care. 2018; 23:(6):458–63. doi:10.1080/13625187.2018.1539162.
    [Google Scholar]
  15. Micks T, MEng AS, Mike Parsons. MD, Tony Locke MD, Peter Rogers MD. Point-of-care ultrasonography training for rural family medicine residentsits time has arrived. Can J Rural Med. 2016; 21:(1):28–29.
    [Google Scholar]
  16. Nwabuobi C, Arlier S, Schatz F, Guzeloglu-Kayisli O, Lockwood CJ, Kayisli UA. hCG: biological functions and clinical applications. Int J Mol Sci. 2017; 18:(10):2037.
    [Google Scholar]
  17. Li H, Liu Y, Wen S, Jia H, Du Y. Evaluation of serum biomarkers and efficacy of MTX in women with ectopic pregnancy. Mol Med Rep. 2019; 20:(3):2902–8. doi:10.3892/mmr.2019.10533.
    [Google Scholar]
  18. Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2017; 1:(1):Cd007223. doi:10.1002/14651858.CD007223.pub4.
    [Google Scholar]
  19. Pawde AA, Ambadkar A, Chauhan AR. A study of incomplete abortion following medical method of abortion (MMA). J Obstet Gynaecol India. 2016; 66:(4):239–43. doi:10.1007/s13224-015-0673-1.
    [Google Scholar]
  20. Sakhavat L, Baiki O, Hashemi-Nejad M. Evaluation of results of medical treatment of first trimester incomplete abortion with methyl ergonovine maleate (methergine). SSU_Journals. 2004; 12:(1):29–34.
    [Google Scholar]
  21. Gemzell-Danielsson K, Kallner HK, Faúndes A. Contraception following abortion and the treatment of incomplete abortion. Int J Gynaecol Obstet. 2014; 126: Suppl 1:S52-S55. doi:10.1016/j.ijgo.2014.03.003.
    [Google Scholar]
  22. Rouse C, Eckert L, Muñoz F, Stringer J, Kochhar S, Bartlett L, et al. Postpartum endometritis and infection following incomplete or complete abortion: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine. 2019; 37:(52):7585–95. doi:10.1016/j.vaccine.2019.09.101.
    [Google Scholar]
  23. Dayananda I, Maurer R, Fortin J, Goldberg AB. Medical abortion follow-up with serum human chorionic gonadotropin compared with ultrasonography: a randomized controlled trial. Obstet Gynecol. 2013; 121:(3):607–13. doi:10.1097/AOG.0b013e3182839fda.
    [Google Scholar]
  24. Clark W, Panton T, Hann L, Gold M. Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. Contraception. 2007; 75:(2):131–5. doi:10.1016/j.contraception.2006.08.001.
    [Google Scholar]
  25. Pocius KD, Maurer R, Fortin J, Goldberg AB, Bartz D. Early serum human chorionic gonadotropin (hCG) trends after medication abortion. Contraception. 2015; 91:(6):503–6. doi:10.1016/j.contraception.2015.03.004.
    [Google Scholar]
  26. Reeves MF, Fox MC, Lohr PA, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol. 2009; 34:(1):104–9. doi:10.1002/uog.6404.
    [Google Scholar]
  27. Peng Y, Wu D, Chen L. The diagnosis of acephalocystis racemose and missed abortion based on transvaginal ultrasonography and serum B-HCG monitoring. Biomed Res J. 2018.
    [Google Scholar]
  28. Senapati S, Barnhart KT. Biomarkers for ectopic pregnancy and pregnancy of unknown location. Fertil Steril. 2013; 99:(4):1107–16. doi:10.1016/j.fertnstert.2012.11.038.
    [Google Scholar]
  29. Taylor AH, Finney M, Lam PM, Konje JC. Modulation of the endocannabinoid system in viable and non-viable first trimester pregnancies by pregnancy-related hormones. Reprod Biol Endocrinol. 2011; 9:(1):152. doi:10.1186/1477-7827-9-152.
    [Google Scholar]
  30. Goksedef BP, Kef S, Akca A, Bayik RN, Cetin A. Risk factors for rupture in tubal ectopic pregnancy: definition of the clinical findings. Eur J Obstet Gynecol Reprod Biol. 2011; 154:(1):96–99.
    [Google Scholar]
  31. van Mello NM, Mol F, Verhoeve HR, van Wely M, Adriaanse A, Boss EA et al. Methotrexate or expectant management in women with an ectopic pregnancy or pregnancy of unknown location and low serum hCG concentrations. A randomized comparison. Hum Reprod. 2013; 28:(1):60–7. doi:10.1093/humrep/des373.
    [Google Scholar]
  32. van Mello NM, Mol F, Ankum WM, Mol BW, van der Veen F, Hajenius PJ. Ectopic pregnancy: how the diagnostic and therapeutic management has changed. Fertil Steril. 2012; 98:(5):1066–73. doi:10.1016/j.fertnstert.2012.09.040.
    [Google Scholar]
  33. Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003; 109:(2):190–5. doi:10.1016/s0301-2115(03)00012-5.
    [Google Scholar]
/content/journals/10.5339/qmj.2021.22
Loading
/content/journals/10.5339/qmj.2021.22
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): Complete medical abortionSerum β-hCG and Transvaginal ultrasound
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error